Axsome Therapeutics (AXSM)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Axsome Therapeutics (AXSM)
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Key Insights
Critical company metrics and information
Share Price
$99.54Market Cap
$4.82 BillionTotal Outstanding Shares
48.46 Million SharesTotal Employees
589Dividend
No dividendIPO Date
November 19, 2015SIC Description
Pharmaceutical PreparationsHomepage
https://www.axsome.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow | $-89.22 Million |
Net Cash Flow From Investing Activities, Continuing | $247000.00 |
Net Cash Flow From Financing Activities, Continuing | $43.59 Million |
Net Cash Flow From Investing Activities | $247000.00 |
Net Cash Flow From Operating Activities | $-132.57 Million |
Net Cash Flow, Continuing | $-89.22 Million |
Net Cash Flow From Financing Activities | $43.59 Million |
Net Cash Flow From Operating Activities, Continuing | $-132.57 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Operating Income/Loss | $-306.22 Million |
Other Operating Expenses | $96.91 Million |
Research and Development | $162.87 Million |
Costs And Expenses | $644.68 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Diluted Earnings Per Share | $6.58 |
Income/Loss From Continuing Operations After Tax | $-310.95 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-310.95 Million |
Selling, General, and Administrative Expenses | $384.90 Million |
Income/Loss From Continuing Operations Before Tax | $-311.28 Million |
Operating Expenses | $644.68 Million |
Income Tax Expense/Benefit | $325000.00 |
Basic Earnings Per Share | $6.58 |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Revenues | $338.46 Million |
Benefits Costs and Expenses | $649.74 Million |
Diluted Average Shares | $143.75 Million |
Basic Average Shares | $143.75 Million |
Net Income/Loss Attributable To Parent | $-310.95 Million |
Net Income/Loss | $-310.95 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Noncurrent Liabilities | $272.37 Million |
Liabilities | $468.56 Million |
Other Non-current Assets | $33.16 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Equity Attributable To Parent | $92.90 Million |
Other Current Liabilities | $112.57 Million |
Liabilities And Equity | $561.46 Million |
Fixed Assets | $683000.00 |
Accounts Payable | $64.25 Million |
Current Liabilities | $196.19 Million |
Wages | $19.37 Million |
Current Assets | $479.11 Million |
Equity | $92.90 Million |
Intangible Assets | $48.50 Million |
Noncurrent Assets | $82.34 Million |
Assets | $561.46 Million |
Inventory | $14.27 Million |
Other Current Assets | $464.85 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.